Explosion of data in the field has made it impossible to perform an evaluation study without the help of computers. As the data extend every years, it is expected that the need of in silico techniques will be greater. in silico drug screening techniques, which require less effort, are cheaper and faster compared to wet-lab work, are necessary in both the near future and in the long term. Improvement of these kind of techniques has a great importance not only for the exploration of new targets, but also being as original screening-techniques.

In the field of anti-cancer drugs, drug candidates will be screened in silico. This process will not only be used for cancer therapeutics, but also be applied to diseases with very well known molecular pathology such as obesity, diabetics, cardiovascular diseases and neurological diseases. Obtained targets will be biologically tested and will be evaluated by a second screen.

Both the plant-originated molecule bank and the in silico pre-selected molecules will be used in the development of target-oriented, novel drugs. In this context, novel drug candidates capable of neutralizing molecules that become hyper-activated in cancer will initially be tested in vitro on cancer cell lines, and those drug candidates that pass through this first step will then be subjected to preclinical tests in animals. In these tests, cancer models generated in genetically-modified mice will be used.